X
<

Where Sanofi Stands after the 3Q17 Results

PART:
1 2 3 4 5 6 7 8
Part 5
Where Sanofi Stands after the 3Q17 Results PART 5 OF 8

Checking in with Sanofi’s Diabetes and Cardiovascular Business in 3Q17

Diabetes and cardiovascular franchise

Sanofi’s (SNY) diabetes and cardiovascular franchises include the blockbuster diabetes drug Lantus, which contributes over 70% of total revenues for diabetes products. For 3Q17, these franchises’ combined revenues fell 9.1% at constant exchange rates to 1.67 billion euros, including sales from emerging markets.

Checking in with Sanofi’s Diabetes and Cardiovascular Business in 3Q17

Interested in SNY? Don't miss the next report.

Receive e-mail alerts for new research on SNY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

After excluding the revenues for emerging markets, the diabetes and cardiovascular franchises reported revenues of 1.30 billion euros for 3Q17—a 14.8% YoY (year-over-year) fall.

Diabetes

The diabetes franchise reported revenues of 1.55 billion euros in 3Q17—a 10% YoY fall, including revenues from emerging markets. After excluding the revenues from emerging markets, the franchise reported revenues of 1.18 billion euros for 3Q17, or 16.3% lower YoY.

Lantus, the blockbuster drug in the diabetes franchise, reported revenues of 867 million euros in 3Q17, or 22% lower YoY, excluding revenues from emerging markets. US sales for Lantus fell 25.4% YoY to 608 million euros, while European sales fell 14% YoY to 184 million euros in 3Q17.

Toujeo, another drug from the diabetes franchise, reported a 14% YoY rise at constant exchange rates to 179 million euros, excluding revenues from emerging markets. This growth in revenues was driven by increased sales across all international markets, excluding US markets, which reported a 6.6% fall in US sales.

Cardiovascular

Multaq and Praluent—two drugs from Sanofi’s cardiovascular franchise—reported a combined 4% YoY rise in revenues at constant exchange rates to 123 million euros in 3Q17, including the revenues from emerging markets. Multaq sales fell to 80 million euros, excluding emerging markets—a 4.6% fall—driven by lower US sales. Praluent revenues rose 26.5% YoY at constant exchange rates to 41 million euros, excluding emerging markets.

Notably, the BLDRS Europe Select ADR ETF (ADRU) has 22.3% of its total investments in the healthcare sector, with 6.3% in Novartis AG ADR (NVS), 3.0% in Sanofi ADR (SNY), 2.5% in GlaxoSmithKline ADR (GSK), and 2.4% in AstraZeneca ADR (AZN).

X

Please select a profession that best describes you: